Further Information
TAZ, tafazzin (cardiomyopathy, dilated 3A (X-linked) endocardial fibroelastosis 2 Barth syndrome) , HGNC:11577, BTHS, CMD3A, EFE, EFE2, G4.5, XAP-2 , OTTHUMP00000061673, cardiomyopathy, dilated 3A (X-linked), tafazzin, XX-FW83563B9.3, FLJ27390, Taz1, LVNCX
Peptide ELISA: antibody detection limit dilution 1:32000.Western Blot:Approx 28kDa band observed in Human Heart lysates (calculated MW of 33.5kDa according to NP_000107.1, 30.2kDa according to NP_851828.1, 31.7kDa according to NP_851829.1 and 28.5 according to NP_851830.1). Recommended concentration: 0.3-1.0 ug/ml.
- Brandner K, Mick DU, Frazier AE, Taylor RD, Meisinger C, Rehling P. Taz1, an outer mitochondrial membrane protein, affects stability and assembly
of inner membrane protein complexes: implications for Barth Syndrome. Mol Biol Cell. 2005 Nov;16(11):5202-14.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Expected Species Reactivity based on sequence homology: Mouse, Rat, Dog
The immunogen for this antibody is: C-HLKTQAEQLHNH
6901
tafazzin
TAZ
Homo sapiens
Liquid
NP_000107.1, NP_851828.1, NP_851829.1, NP_851830.1
4507371
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Cancer
This antibody is expected to recognise isoforms 1to 4 (NP_000107.1; NP_851828.1; NP_851829.1; NP_851830.1, respectively).
Q16635